Compare TRT & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRT | RNXT |
|---|---|---|
| Founded | 1958 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1M | 36.4M |
| IPO Year | N/A | 2021 |
| Metric | TRT | RNXT |
|---|---|---|
| Price | $10.30 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 27.2K | ★ 295.1K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $42,188,000.00 | $928,000.00 |
| Revenue This Year | N/A | $2,795.35 |
| Revenue Next Year | N/A | $272.69 |
| P/E Ratio | $146.08 | ★ N/A |
| Revenue Growth | ★ 0.10 | N/A |
| 52 Week Low | $4.62 | $0.70 |
| 52 Week High | $9.90 | $1.69 |
| Indicator | TRT | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 76.94 | 48.73 |
| Support Level | $9.35 | $0.92 |
| Resistance Level | $9.33 | $0.93 |
| Average True Range (ATR) | 0.58 | 0.06 |
| MACD | 0.13 | 0.02 |
| Stochastic Oscillator | 81.75 | 65.05 |
Trio-Tech International operates in the semiconductor industry, providing manufacturing, testing, and distribution services for semiconductor test equipment and electronic components. It has two main segments: Semiconductor Back-end Solutions (SBS) and Industrial Electronics (IE). The SBS segment, which generates the majority of the Company's revenue, focuses on manufacturing equipment for semiconductor back-end processes, offering testing services, and distributing burn-in test related equipment. The IE segment manufactures equipment for other industries and distributes electronic products outside the semiconductor sector. The Company operates in the United States, Singapore, Malaysia, Thailand, and China, serving customers across multiple regions.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.